Introduction Given that adverse drug effects (ADEs) have led to post-market patient harm and subsequent drug withdrawal, failure of candidate agents in the drug development process, and other negative outcomes, it is essential to attempt to forecast ADEs and other relevant drug-target-effect relationships as early as possible. Current pharmacologic data sources, providing multiple complementary perspectives on the drug-target-effect paradigm, can be integrated to facilitate the inference of relationships between these entities. Objective This study aims to identify both existing and unknown relationships between chemicals (C), protein targets (T), and ADEs (E) based on evidence in the literature.
Introduction
Adverse drug effects (ADEs) are non-preventable, negative pathological or physiological consequences resulting from the use of a drug product that may or may not manifest as adverse drug reactions (ADRs) [1] . Between 1999 and 2006, annual rates of ADR-related mortalities were as high as 0.12/100,000 cases in the USA [2] . Because ADRs are notoriously underreported, the annual morbidity and mortality rates may actually be much higher [2] . ADRs significantly increase hospital length of stay and overall cost of hospitalization [3] , and contribute to the annual US$5.6 billion in adverse drug event costs according to the US Agency for Healthcare Research and Quality [4] .
Anticipating and managing ADEs have been critical areas of research for decades. Indeed, the structure of the US Food and Drug Administration's (FDA) new drug approval process allows for multiple opportunities to identify ADEs before the drug candidate reaches the market. Furthermore, post-marketing surveillance may discover additional ADEs, especially ones that occur infrequently. Nevertheless, rare but severe ADEs have caused several drugs to be withdrawn from the market, e.g., the non-steroidal anti-inflammatory drug (NSAID) pirprofen in 1990 for fatal hepatotoxicity, the antihistamine terfenadine in 1998 for a prolonged corrected QT (QT c ) interval, and the HMG-coA reductase inhibitor (statin) cerivastatin in 2001 for increased risk of rhabdomyolysis [5] .
Informatics techniques have been pursued to study ADEs. For instance, Don Swanson developed the following text-mining inference paradigm [6] using published literature: if an article associated a chemical entity (A) with a physiological process (B), and if another article associated the same physiological process (B) with an effect (C), then an association between chemical (A) and effect (C) could be inferred. Swanson used this ABC paradigm to correctly predict that magnesium supplementation would reduce the occurrence of migraines, an inference that has been subsequently validated experimentally [7] .
The publicly accessible FDA Adverse Event Reporting System (FAERS) database [8] is a critical tool for identifying rare ADEs in post-marketing surveillance. There have been efforts to mine FAERS for drug interaction adverse events [9] . Electronic health records (EHRs) and MEDLINE have also served as knowledge bases for other data mining investigations [10] . A detailed review of available data sources for systems pharmacology is available from Bai and Abernethy [11] .
In silico strategies to predict drugs' off-and on-target interactions as well as associated adverse and therapeutic effects have been actively pursued (Table 1) . A substantial number of those computational studies were dedicated to drug repurposing (Table 1 ; 'C-T' or 'C-D' in the 'Goal' column). For example, Campillos et al. [17] used side effect profile similarity to impute new pharmacological targets for known drugs, while Lounkine et al. [18] employed structural similarity of drugs. Yang and Agarwal [12] used side effects as features of drugs to build classification models of drug indications, while Simon et al. [22] used protein interaction profiles of drugs. Moreover, there are many studies focusing on large-scale prediction of chemical-protein interactions per se [26, 27] , which can provide useful input. Another group of studies derives statistical models to predict drug side effects (Table 1 ; 'C-E' in the 'Goal' column) based on chemical structure, drug-target interaction profiles, and even drug indications as features [13] [14] [15] 24] .
Finally, an increasing number of studies attempt to consider the entire network of drug/target/effect relationships (Table 1 ; 'Network' or 'Inference' in the 'Methods' column), often reporting the integrated view in the form of a database [19, 20] . Predictions are generated in the form of probabilities of network connections [15] or as networkbased inferences [21] .
Despite these advances, there are still several challenges facing informatics-based ADE prediction. Collections such as FAERS are voluntary; many ADE occurrences are not reported due to a perceived lack of time or utility on the part of the clinician or patient. Case reports may or may not be able to discern a mechanistic explanation for observed drug-ADE associations. Mining of EHR data has proven fruitful for establishing ADEs [28] , clinical trajectories [29] , and other endpoints [30] , though underlying mechanisms for these outcomes can be challenging to elucidate through this approach. Thus, additional approaches for detecting, validating, or identifying mechanisms behind ADEs should be sought. Following Swanson's aforementioned ABC paradigm, this study aims to identify unknown relationships between chemicals (C), protein targets (T), and ADEs (E) based on scientific reports in the literature. The 'chemicals' of interest in this study are compounds recognized as approved or investigational pharmacotherapeutic agents. In our approach, described in detail in Sect. 2, known relationships between chemicals, protein targets, and ADEs are collected initially from several pharmacological and biomedical data sources. These relationships are curated and integrated according to Swanson's paradigm to form C-T-E triangles. They are then priority-scored to facilitate inference of previously unreported C-E relationships.
Materials and Methods

Chemicals (C)
The initial list of chemicals was extracted from the National Institutes of Health (NIH) Chemical Genomics Center's Pharmaceutical Collection (NPC), a publicly accessible database containing around 15,000 approved and investigational drugs [31] . A chemical curation process (Fig. 1 ) pared this list down to 7523 compounds. Since the intended focus of this study was on small-molecule organic compounds, those that were tagged in the NPC as 'biologics', 'inorganics', or 'structure undefined' (these were often mixtures) were removed. Compounds with molecular weight [3 kDa were also removed. Additional inorganics, metalorganics, and mixtures were removed via Pipeline Pilot Professional Client version 9.1 (Dassault Systèmes, Vélizy-Villacoublay, France) and ChemAxon Standardizer version 6.0 (ChemAxon, Budapest, Hungary). Duplicate chemicals detected via canonical SMILES and InChIKey, forms of line notation for chemical substances, were set aside using Knime version 2.6.2 (KNIME AG, Zurich, Switzerland). Our standard automated curation workflow [32] [33] [34] was then applied to the resulting unique active pharmaceutical ingredient (API) list, and additional errors, such as two-dimensional (2D) structural duplicates, were analyzed using HiT QSAR (Hierarchical Technology for Quantitative Structure-Activity Relationships) [35] . Cases in which a mixture was misrepresented by only one compound were removed. Then, incorrect name-to-structure annotations, stereochemistry errors, and structures in certain cases were fixed. In addition, incorrect PubChem compound identifiers (CIDs) were fixed or removed. Secondary to our group's established workflow, multiple entries for the same API were mapped to a single chemical entity. These many-to-one relationships are represented in the online repository (https://dataverse.unc.edu/dataverse/ CTE_Inferences). Although our curation workflow is 
Targets (T)
The list of protein targets was obtained from the Therapeutic Target Database [36] , another publicly accessible database containing pharmacological information on over 2000 known or investigational therapeutic targets. To facilitate the interoperability between multiple data sources, a restricted set of 1280 targets with associated UniProt identifiers (IDs) [37] were retained for this project (Electronic Supplemental Material Figure SF1 ).
Adverse Drug Effects (ADEs) (E)
A list of ADEs was obtained from the Side Effect Resource (SIDER) [38] , a public knowledge source listing of established (known) ADEs of therapeutic agents extracted from the package inserts of the drug products. Only the 4492 ADEs with unique UMLS concept IDs (Unified Medical Language System, version 2013AB [39] ) were retained for this project.
Establishing Pairwise Associations
Known C-T, T-E, and C-E associations, or edges, were collected. C-T edges were obtained from two data sources: the Search Tool for Interactions of Chemicals (STITCH) [40] and the Comparative Toxicogenomics Database (CTD) [41] . STITCH contains information on chemicalprotein interactions for 300,000 small molecules, 2.6 million proteins, and over 1000 organisms. CTD describes associations between chemicals, genes, and diseases in the framework of gene ontology and biochemical pathways, covering 887,000 chemical-gene associations, 13.5 million gene-disease associations, and 1.5 million chemical-disease associations. T-E edges were also obtained from CTD. Known C-E edges were extracted from SIDER, CTD, and ChemoText [42] . ChemoText is a knowledge base of relationships between chemicals, targets, and ADEs extracted from MEDLINE annotations, covering 1.2 million chemical-target associations, 1.9 million target-disease associations, and 9.4 million chemical-disease associations. A summary of the data sources used to obtain these C-T, T-E, and C-E edges is shown in Table 2 . 
Data Curation and Representation
Each data source may refer to its chemicals, targets, and ADEs using different identifier schemes. For example, STITCH refers to chemicals using STITCH IDs (which are derived from PubChem CIDs), whereas CTD uses Chemical Abstracts Service (CAS) registry numbers. Thus, a common identifier scheme for chemicals, targets, and ADEs had to be established. For chemicals, an internal identifier system (Ch0000-Ch7522) was used for the remainder of the study. Although after finishing curation the number of chemicals was decreased to 7448, the original Ch0000-Ch7522 chemical identification scheme was kept. UniProt IDs [37] were selected to refer to targets. UMLS concept unique identifiers and MedDRA Ò Lowest Level Term IDs [43] were used to refer to ADEs. 1 Interconversion between the different identifier schemes was facilitated by UniProt's ID mapping service [37] and the Chemical Translation Service [44] . Likewise, the pool of C-T, T-E, and C-E edges extracted from the various data sources were merged to consolidate information for the same entity that was represented across multiple data sources. The number of C-T, T-E, and known C-E edges before and after merging are listed in Table 2 . Auxiliary information stored with each edge included the number and PubMed IDs (PMIDs) of their article lists in which the edge's vertices, e.g., C and T for a given C-T edge, were co-annotated. These PMIDs were obtained from the data sources informing each edge listed in Table 2 .
Inference Procedure
Swanson's ABC paradigm [6] was used to make C-E inferences in the following way: if an edge existed between chemical C and target T (C ? T), and another edge existed between T and E (T ? E), then an edge between C and E (C ? E) was inferred. It was possible for a C-E inference to have multiple linking targets. That is, C-E could be inferred not only via C ? T 1 and T 1 ? E, but also via C ? T 2 and T 2 ? E. The unique C-E inference was stored with its list of linking targets, as well as the number and PMIDs of articles which were co-annotated with the C-T and T-E edges that informed the C-E inference. After the C-E inferences were made, the entire list of C-E edges could be categorized into three sets: (1) known (i.e., previously reported, and obtained from SIDER, CTD, and/or ChemoText) and inferred C-E; (2) known and not inferred C-E; and (3) inferred and not known C-E.
Inference Scoring
To prioritize C-E inferences for further investigation, three scoring systems were considered for ranking the C-E inferences. Article counts (ACs) described the number of unique articles in which C-T and/or T-E were co-annotated. For example, if chemical C 1 was mentioned with target T 1 in n articles, then C 1 -T 1 would have an AC of n. Several data sources from which edge relations are extracted are already annotated by the source developers. For example, CTD utilizes a combination of manual curation and text mining-assisted ranking/prioritization or articles [41] , and ChemoText utilizes the MEDLINE annotations designated by National Library of Medicine indexers [42] . Linking target counts (LTCs) described the number of linking targets bridging the C-E inference. For [45] . Receiver operating characteristic (ROC), ROC enrichment, and precision-recall (PR) curves were used to compare the performance of each scoring system and select one scoring system for ranking C-E inferences. Known C-E edges were used as the 'true' cases, while the inferred C-E edges were decoy cases. The prioritization procedure ranks all inferences (based on a particular metric score), then takes various top portions (L) of the ranked list as the 'predicted positive' part (with the remainder [^L] being 'predicted negative'). This affords calculation of 'true positives' (known associations in L), 'false positives' (other inferences in L), 'false negatives' (known associations in^L), and 'true negatives' (other inferences in^L). This process is repeated for progressively larger portions of the ranked list and essentially reveals how well the scoring method retrieves known associations.
Substudy 1: Restriction of Target and ADE Lists
To facilitate closer analysis of the C-E inferences, the lists of targets and ADEs were reduced. The known C-T and T-E edges were analyzed to find the top 100 occurring targets in each set of known C-T and T-E edges. The union of these sets of targets would be retained from the original target list. Similarly, the set of ADEs was filtered to retain the 'pharmacovigilance-relevant' ADEs, which have been associated with drugs' market withdrawal, black box warnings, and/or hospitalizations based on analysis of scientific literature, FAERS, and other biomedical references [46, 47] . It was anticipated a priori that there would be many inferred C-E edges, and narrowing down potential sets of C-E inferences to be inspected further helped make the additional investigations more tractable. Also, not all targets and effects are clinically informative (e.g., nausea is fairly non-specific). Selecting a reduced set of targets and effects to evaluate further serves as a pilot study for the ability to view these relations at multiple levels of granularity.
Substudy 2: Restriction of ADE List Only
Out of concern that limiting the set of targets to just the most promiscuous targets would result in 'noisy' inferences (i.e., many C-E inferences would be ranked equally by LTCs), the restrictions on the target list were lifted, and only the set of ADEs was limited to those that were pharmacovigilance-relevant as described in Substudy 1.
Substudy 3: Inference and Inference Strategy Validation
This inference strategy was validated in several ways. Case reports linking a chemical and ADE for a given C-E inference, and published after the C-E inference was made, provided primary literature confirmation for some C-E inferences. The proportion of known C-E associations captured by inferred C-E associations was computed. Additional inference strategy validation was conducted via a time-split validation technique, with the aims of (1) validating the forward-prediction abilities of the ABC inference strategy; and (2) evaluating the proportion of C-E inferences that could be confirmed over time. All edges from the described integrated knowledge base were further characterized by timestamping, which overall sought to identify the earliest year by which an edge could be established. For known C-T, T-E, and C-E edges with article lists (i.e., papers that co-annotate or establish an association between known C-T, T-E, or C-E associations), their timestamps were determined by the earliest publication year of the papers in their article lists. If a known edge was listed in its data source(s) without an article list, no timestamp was assigned. For inferred C-E associations, their timestamps were determined by the later of the constituent C-T and T-E edges' timestamps. That is, the timestamp represents the latest year at which there was enough information on a C-T and/or T-E association so that the C-E inference could be made. If either the constituent C-T or T-E edge did not have a timestamp, the inferred timestamp of the C ? E edge defaulted to that of whichever edge did have an assigned timestamp.
The timestamping validation was conducted as shown in Fig. 2. 
Results
From the selected data sources (Table 2 ) and after additional rounds of chemical curation, 7448 chemicals, 1280 targets, and 4492 ADEs, as well as 76,400 C-T edges, 1,128,542 T-E edges, and 362,408 known C-E edges, were extracted. Electronic Supplementary Material Figure SF2 depicts the extent of the entities covered by the identified edges based on raw data. It is acknowledged that the biomedical literature grows each day with new C ? E associations and other discoveries. Significant changes to our results are not expected, but minor changes in the size of the data and some of the derivative values may occur.
Among chemicals with at least one connection, 44% were associated with five or fewer targets; at the same time, 39% of such chemicals had associations with over 100 ADEs (Electronic Supplementary Material Figure SF3 ).
Once information regarding vertices (chemicals, targets, and ADEs) and edges was compiled and organized into CTE triangles, 5,841,274 unique C-E associations were inferred. These correspond to * 17% of all possible associations in a matrix of 7448 chemicals and 4492 ADEs, i.e., 83% sparsity. This CTE network is visualized in Fig. 3 . There were 341,453 C-E edges that were both previously reported (known) and inferred from the ABC strategy (Fig. 4) . Inference of C-E edges via the ABC paradigm was able to capture 94% of the known C-E edges. The majority of inferred C-E edges (57%) had few (B 5) linking targets.
Substudy 1: Restriction of Target and ADE Lists
The restriction of the set of targets provided a list of 153 targets (see online repository at https://dataverse.unc.edu/ dataverse/CTE_Inferences), retained from the original (n = 1280) target list. From the C-T edge list, the most common targets were cytochrome P450 subtype 3A4 (CYP3A4), tumor necrosis factor (TNF)-a, and multidrug resistance protein 1 (MDR1). The set of ADEs was filtered to retain 164 ADEs that were 'pharmacovigilance-relevant' (see online repository at https://dataverse.unc.edu/ dataverse/CTE_Inferences). There were 47,078 C ? E inferences remaining after the number of targets and ADEs were reduced (new sparsity: 96%). Pulmonary valve incompetence, thrombocytopenic purpura (TP), and aortic valve incompetence were the three most common ADEs.
Of the three scoring systems considered, AC appeared to have the best overall performance (by area under the ROC) in this reduced C-E inference set, though LTC had the best early enrichment (i.e., more known C-E associations ranked higher in priority listing). The top 45 LTC-prioritized C-E inferences ('generated hypotheses') were selected for further investigation (Electronic Supplementary Material Table ST1 ).
Substudy 2: Restriction of ADE List Only
When just limiting the set of ADEs to those that were pharmacovigilance-relevant (164 ADEs), there were 286,815 C-E inferences remaining from the original * 6 million C-E inferences (new sparsity: 77%). There were 76 unique ADEs represented. Drug-induced liver disease, renal failure acute, acute renal insufficiency, For this ADE-only limited C-E inference list, LTC appeared to have the best overall performance for separating known inferences (area under the ROC = 0.84; Fig. 5a ), though MI had the best early enrichment (* 100-fold at 0.01% of the ranked list; Fig. 5b ). The C-E inferences were thus sorted by MI, and the top ten prioritized C-E inferences by each scoring system are shown in Table 3 .
Substudy 3: Inference and Inference Strategy Validation
Case studies were identified from primary literature published after the inference was made (the latter date being, at the latest, 11 January 2013). When the restricted targets/ restricted ADEs list of C-E inferences were prioritized by LTC, the inference between paroxetine and TP being ranked first. Paroxetine, a selective serotonin reuptake inhibitor, was linked to TP via 22 targets (see Fig. 3 ). These targets include caspase-3 (CASP3) and signal transducer and activator of transcription 3 (STAT3). Paroxetine increases CASP3 activation. CASP3 activation is associated with idiopathic TP [48] , and its inhibition is associated with blocking apoptosis mediated by plasma from thrombotic TP and hemolytic-uremia syndrome patients [49] . Paroxetine suppresses STAT3 expression [50] , and decreased STAT3 dimerization and general lack of Janus kinase 2 (JAK2) pathway activation is associated with TP [51, 52] . When the restricted ADEs list of C-E inferences was prioritized by MI, the inference between testosterone and myocardial infarction via 183 linking targets ranked ninth. These targets include TNF-a and c-Fos. Testosterone increases TNF-a production [53] . While the relationship between increased TNF-a production and myocardial infarction is not definitively a causative one, increased levels of the inflammatory cytokine have been observed during initial and recurrent myocardial infarctions [54] , and have been associated with post-event myocardial injury [55] . Similarly, testosterone induces c-Fos expression [56] , which may have a role in myocardial infarction pathogenesis [57] . The FDA has required labeling changes regarding the potential cardiovascular risk of testosterone [58] , in part due to two independent retrospective studies [59, 60] that found an association between testosterone and negative cardiovascular outcomes, including myocardial infarction and stroke. However, the findings of these studies are controversial because of methodological concerns as well as prior evidence that (1) low testosterone levels have been associated with increased cardiovascular events; and 2) testosterone replacement therapy for patients with low testosterone has been associated with reduced cardiovascular events [61] .
The top 50 MI-ranked C-E inferences (again, restricted by pharmacovigilance-relevant ADEs) were selected for Fig. 3 Network visualization of a interconnected chemicals (blue), targets (green), and adverse drug effects (red); b connectivity clusters in each domain; and c a subnetwork for the paroxetine-thrombocytopenic purpura inference. 5HT2C serotonin receptor subtype 2C, AChE acetylcholinesterase, ADRB1 adrenergic beta-1 receptor, CASP3 caspase-3, COX2 cyclooxygenase-2, CYP1A2 cytochrome P450 subtype 1A2, CYP2B6 cytochrome P450 subtype 2B6, CYP2C19 cytochrome P450 subtype 2C19, CYP2C9 cytochrome P450 subtype 2C9, CYP2D6 cytochrome P450 subtype 2D6, CYP3A4 cytochrome P450 subtype 3A4, DRD2 dopamine D2 receptor, eNOS endothelial nitric oxide synthase, FOS proto-oncogene c-Fos, iNOS inducible nitric oxide synthase, MAOA monamine oxidase type A, MAOB monamine oxidase type B, MDR1 multidrug resistance protein 1, MRP2 multidrug resistance-associated protein 2, PRL prolactin, STAT3 signal transducer and activator of transcription 3, TNF-a tumor necrosis factor alpha Table ST2 ). When reviewing the biomedical literature for inference validation, nine (18%) of these inferences appear to have a causal relationship, nine (18%) appear to have a protective/effect-mitigating relationship, six (12%) appear to have mixed effects, four (8%) appeared to have no effect (i.e., incorrect inference), and 22 (44%) could not be confirmed. This does not mean that these inferences were erroneous, but no articles that co-annotated the drug and effect could be found to the authors' knowledge as of this writing.
Other inferences that were validated in the literature reports that appeared after the publications used for making the inference include ciprofloxacin ? posterior reversible encephalopathy syndrome (PRES) [62] and rifaximin ? toxic epidermal necrolysis syndrome (TENS) [63] .
Following the workflow illustrated in Fig. 2 , the first aim of the time-split validation was to evaluate how well the ABC inference strategy predicts later-known C-E associations. Consider the example of a cutoff year of 1992 (Step 2 of Fig. 2 ). There were 241,817 known C ? E associations established (i.e., with timestamp) after 1992 (Step 3). Based on the C ? T and T ? E associations AUC area under the curve, C-E chemical-effect, DB database creation, MI mutual information, ROC receiver operating characteristic established prior to 1992, there were 497,537 C ? E inferences that could be made prior to 1992, of which 69,844 C ? E inferences were also confirmed after 1992 (Steps 4-5). This yields a post-1992 coverage rate of 69,844/241,817 = 29%, i.e., 29% of C-E associations established after 1992 could have been inferred using the described ABC strategy prior to 1992 (Step 6). In addition, the time-split validation assessed the rate of C ? E inferences that would later be validated post-cutoff year. There is a validation rate of the pre-1992 C ? E inferences of 69,844/497,537 = 16%, i.e., 16% of C-E inferences that could have been made prior to 1992 were later confirmed (Step 6). These steps were repeated in 5-year increments for the years 1987-2007 (Fig. 6) . b Pre-cutoff year validation rates from time-split validation. The percentage of C ? E inferences that could be made prior to a given cutoff year that were later validated. The total number of inferred C ? E edges that could be established prior a given cutoff year is listed above each bar. C chemical, E adverse drug event, C-E chemical-effect, T target
Discussion
In this work, publicly available knowledge bases describing known associations between pharmacotherapeutic agents, targets, and ADEs were used to infer unknown associations between drugs and ADEs. While our strategy was able to recover 94% of previously reported C-E associations, there was still a small fraction (* 21,000) of known C-E associations that remained unpredicted. This may occur if no targets are discovered during the initial data collection and curation steps that link C to E, or it could happen for known C-E associations if the pathophysiology behind the association has not been fully elucidated. For example, the bisphosphonate alendronic acid is known to cause osteonecrosis of jaw (ONJ), and this pair is on our list of previously reported C-E associations. However, it could not be inferred through the ABC strategy since the alendronic acid-T associations and T-ONJ shared no common linking targets. The mechanism linking bisphosphonates to ONJ is still not well-understood [64] .
The results of our study compare favorably with those of previous computational approaches to ADE prediction. Yamanishi and colleagues [13] used several approaches to analyze 658 drugs, 969 ADEs, and 23,061 drug-ADE associations. The best-performing one yielded an area under the PR curve (AUPR) of 0.21 ± 0.0024. When scoring by MI, our inference strategy yielded an AUPR of 0.48 (Fig. 5c ). Mathur and Dinakarpandian [25] used network analysis techniques on known relations between drugs, targets, and diseases to predict associations between biological processes and drugs. Several databases, including Swiss-Prot, OMIM (Online Mendelian Inheritance in Man), and GeneRIF (Gene Reference Into Function), were used to inform known relationships. They report 2222 drug-disease associations involving 76 drugs and 169 diseases, of which 144 (6.4%) were confirmed in DrugBank [25] . Of the * 6 million C-E inferences produced with the ABC strategy described earlier, 341,453 (5.8%) C-E inferences were confirmed in SIDER [38] , ChemoText [42] , and/or CTD [41] (Fig. 4) . Despite our lower confirmed C-E rate, a larger number of chemicals and effects were included for consideration in this study, with the C-E inferences involving 4053 chemicals and 1743 effects (raw data). 'Chemicals' include not only drugs but also drug-like compounds, whose physiologic effects may not be as well characterized as drugs in most of the available pharmacology or ADE databases.
The time-split validation identified 'novel' C-E inferences at 5-year timepoints from 1987 to 2007 (Fig. 6) . The percentage of known C-E associations that could have been predicted earlier increased over time, while the percentage of inferred C-E associations that were later confirmed appeared to decrease over time. Both these trends are likely due to the natural growth of information (discoveries about C-T and T-E) available over time, combined with the decreasing number of C-E associations established after the cutoff year, as the cutoff year increases.
There are several aspects of this approach that are of benefit in clinical pharmacovigilance. A case report can take some time to develop from observation to publication, and therefore into discoverable public knowledge. The approach in the present work provides a method for using data already gathered to potentially corroborate an ADE noticed in practice, in less time than it would typically require for said case report to get published and discovered. The described inference approach was designed to draw from publicly available (i.e., free to access) knowledge bases; access to proprietary databases may be cost-prohibitive and difficult to maintain long-term. Our study seeks to build on the multiple in silico studies [12-25, 28-30, 65-72] that have evaluated the CTE relationship by integrating heterogeneous data resources bridging molecular pharmacology through clinical surveillance in scope, and ranging from traditional biochemical studies through to text mining (e.g., ChemoText [42] ) in the origin of assertions. While limits can be imposed on the types of drugs, targets, and ADEs returned, our integrated databases resource was not built with these limits in place and therefore affords some measure of flexibility by interest area.
This study had certain limitations. The inference strategy is limited by the 'universe' of knowledge it is based on, which affects both the quantity and quality of inferences.
Only an association between a chemical and an ADE can be inferred; it is not possible to distinguish, without further characterization of edges, between causative, therapeutic, or no-effect C-E associations. It may be computationally expensive to update the current collection of C-T, T-E, known C-E, and inferred C-E edges, since new associations would need to be made, integrated into the current framework, and have scores revised. This inference strategy does not replace clinical judgment; in fact, manual intervention is required to process even the prioritized list of C-E inferences. For example, 'Convulsion', 'Convulsions generalized', 'Clonic convulsion', and 'Convulsive seizure' are all considered separate concepts in this CTE system but have been manually grouped together as seizure, especially if they were all inferred to be associated with the same chemical with the same ranking score. This explains why there are some older dates listed in the 'previously unreported' C-E association list (see Electronic Supplementary Material Tables ST1 and ST2 ), in that the C-E association could have been identified and linked with an ADE synonym not accounted for in the current framework. Moreover, this inference strategy does not attempt to predict the dose at which an ADE would occur for a particular agent, nor does it predict the frequency of this ADE occurring with exposure to the agent. A scoring system that integrates the optimal characteristics of the metrics featured in the present work may be able to provide a more refined prioritized C-E inference list.
There are several future directions that could be explored. Identifying other subsets of C-E inferences for further study, as well as improving the scoring system used to prioritize C-E inferences, may be instructive. One way would be to obtain prioritization ranks based on each metric and then work with these ranked lists, using various rank-merging algorithms. Though pharmacovigilance-relevant ADEs were the focus of the current study, it would be interesting to investigate inferences implicating the top 200 marketed drugs, or to focus on inferences involving G-protein-coupled receptors, many of which are drug targets and/or mechanisms of drug interactions. The same inference strategy could be used for drugs in the development pipeline, to identify potential ADEs that the drug could cause prior to in vivo testing. New ADE predictions could be made or strengthened based on structural similarity with chemicals participating in known C-E associations. Rules of similarity for chemicals sharing the same target and ADE could be rationalized. Inferences could be made for not only C-E associations, but also C-T and T-E edges. These studies may help elucidate a drug's mechanism of action or off-target effects, or link pharmacological action at a target with a specific ADE. The results of these hypothesis-generating investigations could be further validated (or refuted) using basic science, clinical, and computational approaches.
Conclusion
The increasing costs of bringing new drug entities to market strongly motivates the search for in silico methods of identifying the ADEs of a drug candidate early in the development process. We created and characterized an integrated knowledge base of C-T, T-E, and C-E associations, grounded in publicly available pharmacology databases. We used this knowledge base to investigate the feasibility and performance of Swanson's ABC inference paradigm to predict ADEs for selected drugs and drug-like compounds. This inference strategy generated a large volume of C-E hypotheses, which were prioritized for further investigation using scoring methods. Many inferences were validated post hoc, as demonstrated by identified case reports and our timestamping validation. Our strategy could be used to identify previously unreported C-E associations for further investigation. Given the hypothesis-generating nature of the study, this strategy is well-suited for user groups in the research, development, and academia spaces as a springboard for further investigations into the mechanisms behind a C-T, T-E, or C-E association, or groups of these relations thereof. Regulatory groups such as the FDA might find utility in this knowledge base as one resource that might lend further credence to a detected pharmacovigilance signal, as this resource represents the integration of pharmacological and biomedical literature data. This has implications in saving time and cost in drug development, as well as patient outcomes in terms of being better equipped to anticipate ADEs.
